SANTA MONICA, Calif., Sept. 16, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, President and Chief Executive Officer, will provide an overview of the Company at the 21st Annual BioCentury NewsMakers Conference during a live presentation at 11:30am ET. Dr. Belldegrun will also be available to participate in one-on-one meetings with investors who are registered to attend the conference. The event will be held at the Millennium Broadway Hotel & Conference Center in New York. A live webcast will be accessible through Kite's website at www.kitepharma.com in the Investors section under Events & Presentations. A replay will also be available.
About Kite Pharma, Inc.
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing novel immunotherapies and other oncology treatments. Kite is based in Santa Monica, CA.
CONTACT: Kite Pharma Cynthia M. Butitta Chief Financial Officer and Chief Operating Officer 310-824-9999 For Media: Justin Jackson For Investor Inquiries: Kimberly Minarovich Burns McClellan 212-213-0006 firstname.lastname@example.org email@example.comSource:Kite Pharma, Inc.